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Schizophrenia, 17
fats & lab rats
Teresa du Bois

DEPARTMENT of BIOMEDICAL SCIENCE

Last year I joined a dedicated research group on a quest to discover what causes
schizophrenia. My honours project was designed to investigate whether fats, as
part of the structure of cell membranes, could alter neurotransmitter function in
the brain and potentially play a role in the disease. I found that fatty acids can
influence neurotransmitter receptor binding in the rat brain, and may play some
role that can be related to schizophrenia. In this article I provide an introduction
to the science of schizophrenia and discuss new techniques that are available to
study the disorder and insights into my own research findings.
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Introduction
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What is schizophrenia? Schizophrenia is a mental illness that has puzzled scientists
for many decades, and still remains largely unresolved as to its cause. It affects
approximately one in every hundred people, and is a significant burden on health
expenditure in Australia.1The illness interferes with mental functioning and, in
the long-term, may cause changes to a person's personality. The consequences
of having schizophrenia can be massive, both on the sufferer and their family (for
example, see the recent media attention on the Baxter detainee, Cornelia Rau).
Symptoms include hallucinations, delusions and thought disorganisation, as well
as impaired motivation and decreased emotional expression.
It is generally accepted that schizophrenia involves imbalances in signalling
chemicals of the brain called neurotransmitters. Neurotransmitters are proteins
that carry information from cell to cell, or as they are called in the brain, neuron
to neuron. These chemicals form part of pathways that can inhibit or excite
neural cells. An imbalance of these pathways may contribute to symptoms of
schizophrenia by changing the amount of activity in certain brain regions, and
even by causing ceil death, as too much excitation can result in neurotoxicity.
Many, if not all brain regions seem to be involved in schizophrenia, which is not
surprising given the interconnectivity between pathways and systems.
In the past few decades, the most widely studied neurochemical explanation
of schizophrenia has been the dopamine hypothesis, which suggests that
hyperactivity of the dopamine system is the primary pathology of the disorder.
This was based on the fact that antipsychotic drugs, commonly used to treat
schizophrenia, have anti-dopaminergic properties. However this hypothesis has
failed to produce conclusive findings. For one reason, a significant proportion
of schizophrenia patients do not respond to anti-dopamine therapy.2'3 Also,
alterations of various brain regions in schizophrenia do not strictly involve
dopaminergic pathways.
Other popular theories include the neurodevelopmental hypothesis, which
proposes that schizophrenia may be the result of a chemically based injury to
the brain either before or during the critical period of brain development - late
adolescence in humans. This period coincides with the age that schizophrenia
symptoms begin to appear. During this time the brain undergoes 'synaptic
pruning', which basically means getting rid of unnecessary cell signalling pathways
and enhancing useful ones, making the brain more efficient.
There is also emerging evidence in support of the glutamate A/-Methyl-D-aspartate

(NMDA) receptor hypofunction hypothesis. NMDA receptor antagonists such as
phencyclidine (PCP, angel dust) and ketamine (special K) can induce the entire
range of core schizophrenia phenomenology including disorder of attention,
perception and abstract thinking in normal subjects, and can exacerbate
symptoms in patients with schizophrenia,4'5while the psychotic effects produced
by amphetamine (dopamine transporter inhibitor) and lysergic acid (LSD)
(serotonin agonist) do not fully represent the scope of the main symptoms of
schizophrenia.6 Indeed, PCP-induced psychosis is diagnostically difficult to
differentiate from schizophrenia.7 This observation has led many researchers to
believe that glutamate NMDA receptors are the key to unravelling the pathology
of schizophrenia.

There are several methods of examining schizophrenia at the cellular level.
The post mortem brain of schizophrenia has been examined extensively, with
a number of abnormalities detected in many neurotransmitter systems. To
measure the density of neurotransmitter receptors, the procedure involves using
thinly sliced brain tissue sections that are treated with a radioactively tagged
drug that binds to a specific receptor, which is present in the brain sections. To
quantify the amount of radioactivity, and therefore the receptor density, sections
can be exposed to radioactive-sensitive film for several months, then the film is
developed and analysed. Alternatively, sections can be quantified using BetaImager Detection.The University of Wollongong has recently installed a BioSpace
Beta Imager Machine in the Molecular Neurobiology Laboratory, directed by
Associate Professor Xu-Feng Fluang. The Beta Imager is unique in that it can
immediately measure the distribution of beta particles emerging from brain
sections and display them on screen. The image can be directly acquired and
quantified within around four hours,8and it is therefore much more efficient than
film autoradiography. Furthermore, because this is a direct capture of the beta
particle signals, it is significantly more accurate. The Beta Imager was obtained
through funds raised by the local lllawarra community, championed by Lord Mayor
Alex Darling of Wollongong City Council, in partnership with the Neuroscience
Institute of Schizophrenia and Allied Disorders (NISAD). This machine is the first
of its kind available in the southern hemisphere.
Other new techniques available include functional magnetic resonance imaging
(fMRI), where a patient's brain activity is assessed while performing tasks that are
known to activate certain brain regions. Recently, using this technique, a team
of researchers led by NISAD researchers in NSW, found a direct link between
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Techniques available for examining the
cellular basis of schizophrenia

brain structural abnormalities, and core features of the disorder (www.nisad.org.
au). DNA microarray technology is another application of advanced technology
allowing thousands of genes to be analysed for abnormalities simultaneously,
and has been used to identify abnormal genes in schizophrenia.9

Treatment
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Symptoms of schizophrenia patients vary significantly. Typical treatment of
this disorder involves a lifetime of large doses of antipsychotic drugs, which
are only partially effective, expensive, and have many undesirable side effects.
Haloperidol, a first generation 'typical'antipsychotic drug (produced in 1960)
is effective in treating positive symptoms, but it has severe motor side effects.
Second generation drugs such as Olanzapine and Clozapine (produced in 1990)
are known as'atypical'antipsychotics and are effective in treating both positive
and negative symptoms, but can cause severe obesity. A third generation
antipsychotic drug Aripiprazole (produced in 2003) is also effective in treating
both positive and negative symptoms, and it does not cause obesity.

My study
My honours project was designed to see whether fatty acids could alter
neurotransmitter function in the brain, and potentially play a role in the disease.
The study was based on three premises: First, post mortem schizophrenia brains
show lower levels of certain omega-3 and omega-6 fatty acids in their neural
and red blood cell membranes, as well as altered levels of markers for fatty acid
metabolism. Second, many neurotransmitter systems are altered in schizophrenia.
Third, omega-3 fatty acid supplementation in addition to antipsychotic medication
has been shown by some groups to be successful in improving mental health
in schizophrenia patients. This result seems to depend on a dose that optimises
the omega-3 to omega-6 ratio.101wanted to determine if there was a connection
between these findings, that is, is there a relationship between membrane fatty
acid status in the brain, neurotransmitter levels and brain function?
But what have fatty acids got to do with neurotransmitters? In short, all cells
including neurons are surrounded by a membrane that functions as a filter,
allowing only certain materials to pass in and out of the cell. The membrane
itself is embedded with various proteins including neurotransmitter receptors.
Membranes are comprised of phospholipids, which are made up of different
types of fatty acids. It has been shown that rats fed a large percentage of omega3 fatty acids in their diet have a higher ratio of omega-3 fatty acids in their neural
membrane phospholipid composition. The same can be said for other fatty
acid types like omega-6 and saturated fats. Further studies have demonstrated

that by manipulating fatty acid content in the diet and therefore in membrane
phospholipids, the density of neurotransmitter receptors in the brain can be
altered.

I analysed areas throughout the whole brain, and made several interesting
findings.11 Compared to rats on a normal laboratory diet, rats on saturated fat,
omega-3 and omega-6 diets all showed changes in receptor density, but these
were quite varied. The most pronounced effects were seen in the omega-6 fed
group, which showed increased muscarinic receptor binding in several brain
regions. The results illustrate that diet can alter the density of neurotransmitters
in the rat brain. So does this mean that alterations in neurotransmitter receptors
and brain function in schizophrenia are simply due to fatty acid imbalances?
Unfortunately it is not so simple. For one reason, abnormalities in fatty acid levels
in schizophrenia have been attributable to metabolic abnormalities, and not to
a dietary deficiency. It should also be pointed out that abnormal fatty acid levels
could be a consequence of changes in neurotransmitter receptor interaction and
not vice versa. To bring an old cliche to mind, it appears to be a case of which
came first: the chicken or the egg? So while a definitive role for fatty acids in
schizophrenia pathology remains uncertain, studies on the influence of fatty acids
on neurotransmitter receptors do still have potential to improve the treatment of
schizophrenia using dietary fatty acid supplementation.
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In my study, rats were fed diets high in saturated fat, omega-3 polyunsaturated
fatty acid (PUFA), omega-6 PUFA or a control diet for 8 weeks. I examined receptor
subtypes from the serotonin and acetylcholine muscarinic neurotransmitter
systems, both of which have been implicated in schizophrenia in addition to the
popular dopamine and glutamate systems. To do this I needed to do a series of
drug-binding experiments, involving applying a radioligand, which is a radioactive
drug that binds to a certain receptor, to brain sections from the four diet groups.
I measured the amount of radioactivity, and therefore the receptor density, using
both the traditional film method (Fig. 1) and Beta-lmager technology (Fig. 2).
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Fig. 1. Film autoradiography showing the binding pattern of muscarinic M l/
M4 and M2/M4 receptor subtypes in the brain of control rats. Note the similar
distribution of muscarinic receptor subtypes at the level of A and B, while the
distribution of receptor subtypes differs at the level of C. The maps of A to C are
adapted from a standard rat brain atlas indicating the levels that sections were
cut. A'-C': [3H]pirenzepine binding to muscarinic M1/M4 receptor subtypes; A"C": [3H]AF-DX384 binding to muscarinic M2/M4 receptor subtypes. Abbreviations:
Acb: nucleus accumbens; ACC: anterior cingulate cortex; Amg: amygdala; AOP:
anterior olfactory nucleus; CA1-3: CA1-3 fields of the hippocampus; CPU: caudate
putamen; DG: dentate gyrus; PfCx: prefrontal cortex; Tu: olfactory tubercle.
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Fig. 2. Beta-lmager detection showing the binding pattern of serotonin 5-HT2Aand
5-HT2C receptor subtypes in the brain of control rats. Note the similar distribution
of serotonin receptor subtypes at the level of A and B, while the distribution
of receptor subtypes differs at the level of C. The maps of A to C are adapted
from a rat brain atlas and indicate the levels that sections were cut. A'-C: 5-HT2A„
receptors; A"-C": 5-HT2C receptors. Abbreviations: Acb: nucleus accumbens; ACC:
anterior cingulate cortex; Amg: amygdala; AOP: anterior olfactory nucleus; CA1 -3:
CA1-3 fields of the hippocampus; CPU: caudate putamen; DG: dentate gyrus; DM:
dorsomedial hypothalamus; LH: lateral hypothalamus; PfCx: prefrontal cortex;Tu:
olfactory tubercle; VMH: ventromedial hypothalamus.
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Bregma -2.90 mm
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